The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Patient-Focused Drug Development on Chronic Pain; Public Meeting; Request for Comments” as published in the Federal Register on July 11, 2018.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to the Centers for Medicare and Medicaid Services’ (CMS’) proposed Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2019; Medicare Shared Savings Program Requirements; Quality Payment Program; and Medicaid Promoting Interoperability Program (CMS-1693-P).
Press Release: AMCP Urges FDA to Issue Final Guidance on Biosimilar Interchangeability Standards and Provide Education on Substituting Interchangeable Products